Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucravacitinib in early-onset versus long-standing psoriasis vulgaris
jRCTs041240089Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of deucravacitinib in plaque psoriasis (2 cohorts), sponsored by Bristol Myers Squibb. Primary endpoint: Proportion achieving PASI90 or PASI score 1 or lower at week 24. Started Feb 2025; status: active, not recruiting.
02
Drugs
deucravacitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on jRCTs041240089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041240089.